AngioLight Completes Animal Study at Fu Wai Hospital; Begins Preparing for China Food and Drug Administration (CFDA) Regulatory Testing
6/6/2013 10:17:53 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MEDFORD, Mass.--(BUSINESS WIRE)--AngioLight, an early stage, pre-clinical interventional cardiovascular medical device company, has successfully completed an initial animal study of the AngioLight System at Fu Wai Hospital, a leading cardiovascular center located in Beijing. The study paves the way for AngioLight to go forward in China with full-scale animal and clinical testing of the system, which will begin following the anticipated completion of study protocols, hospital review and required China Food and Drug Administration (CFDA) approvals.
Help employers find you! Check out all the jobs and post your resume.
comments powered by